Medication

Pharmaceutical Development Ramp up as Viral Infections Continue to Threaten

Retrieved on: 
Tuesday, March 24, 2020
Health, Articles, Pharmacy, Pharmacology, Pharmaceutical industry, Medication, Active ingredient, Pharmaceutics, Pharmaceutical manufacturing, Pharmaceutical industry in China

Furthermore, the pharmaceutical manufacturing segment is estimated to account for the largest market share in 2019.

Key Points: 
  • Furthermore, the pharmaceutical manufacturing segment is estimated to account for the largest market share in 2019.
  • This industry also includes pharmaceutical API (active pharmaceutical ingredient) manufacturing and pharmaceutical FDF (finished dosage form) manufacturing both of which are expected to grow due to thegrowing drug development activity.
  • Specifically, the number of people who have the virus but don't show symptoms and have not been tested is currently unknown.
  • Yet, studies have shown that it is people without symptoms that are causing substantial amounts of infection.

Data on Ethismos Research Lead Compound, Amitifadine, Reported in Psychopharmacology

Retrieved on: 
Tuesday, March 24, 2020
Pain, Medicine, Health, Antidepressants, Chloroarenes, Amitifadine, Serotonin–norepinephrine–dopamine reuptake inhibitor, Opioid, DOV Pharmaceutical, Pain management, Medication, Psychopharmacology

CAMBRIDGE, Mass., March 24, 2020 /PRNewswire/ --Ethismos Research, developing pharmaceutical treatments for chronic pain management, severe depression, and substance use disorders, announced that research on lead compound, amitifadine, was published online in the peer-reviewed journal, Psychopharmacology , earlier this month.

Key Points: 
  • CAMBRIDGE, Mass., March 24, 2020 /PRNewswire/ --Ethismos Research, developing pharmaceutical treatments for chronic pain management, severe depression, and substance use disorders, announced that research on lead compound, amitifadine, was published online in the peer-reviewed journal, Psychopharmacology , earlier this month.
  • The authors concluded that amitifadine holds promise to counter opioid self-administration in patients taking opioids for pain.
  • Ethismos Research, Inc. is a clinical-stage drug development company developing pharmaceutical treatments for pain, depression, and substance use disorders.
  • Ethismos is continuing the development of the patented small molecule, amitifadine, a triple reuptake inhibitor, originally developed by Euthymics Bioscience, and acquired by Ethismos in 2017.

Global Orphan Drug Market Projected to witness a Growth of 150% by 2026 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 24, 2020
Health, Pharmaceutical, Health, Articles, Pharmaceuticals policy, Pharmaceutical industry, Drug discovery, Food and Drug Administration, Biotechnology law, Orphan drug, Clinical trial, Medication, Orphan Drug Act, Biomedical research in the United States

The "Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" report has been added to ResearchAndMarkets.com's offering.
  • "Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" Report Highlights:
    Global Orphan Drug Market Opportunity: US$ 300 Billion
    US Dominates Global Orphan Drug Market: 50% Market Share
    US Orphan Drug Opportunity To Surpass: US$ 150 Billion
    Global Orphan Drug Clinical Insight: More Than 900 Drugs
    Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs
    Oncology To Dominate Orphan Drug Development: 35% Share
    The research report Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026 discusses about the recent trends and opportunities that the orphan drug market has brought into the pharmaceutical sector.
  • Orphan drugs market has been recently recognized as a promising therapeutic market as the diseases that are covered under the market are life-threatening diseases.
  • Earlier the orphan drug segment was overlooked by the big pharmaceutical companies as developing and marketing of these drugs was considered not so profitable.

Global Antibiotics Market 2020-2024 | Evolving Opportunities with Abbott Laboratories and AbbVie Inc. | Technavio

Retrieved on: 
Tuesday, March 24, 2020
Health, Pharmaceutical, Health, Articles, Pharmaceuticals policy, Antibiotic, Pharmaceutical industry, Abbott Laboratories, Medication

In addition, the growing awareness of various diseases and its treatment is anticipated to boost the growth of the antibiotics market.

Key Points: 
  • In addition, the growing awareness of various diseases and its treatment is anticipated to boost the growth of the antibiotics market.
  • This is propelling the demand for antibiotics and urging key pharmaceutical companies to introduce effective antibiotics.
  • Major Five Antibiotics Market Companies:
    Abbott Laboratories operates the business under various segments such as Established Pharmaceuticals Products, Nutritional Products, Diagnostic Products, and Medical Devices.
  • Antibiotics Market Application Outlook (Revenue, USD Billion, 2020-2024)
    Antibiotics Market Product Outlook (Revenue, USD Billion, 2020-2024)
    Antibiotics Market Drug Origin Outlook (Revenue, USD Billion, 2020-2024)

Europe Pharmaceutical Drugs Market to Reach US$ 219.9 Billion by the End of 2027 - Coherent Market Insights

Retrieved on: 
Monday, March 23, 2020
Health, Articles, Pharmacy, Medical terminology, Pharmaceutical industry, Pharmacology, Chronic condition, Medication, Pharmaceuticals policy, Pharmaceutical industry in China, Healthcare in Iran

Key Trends and Analysis of the Europe Pharmaceutical Drugs Market:

Key Points: 
  • Key Trends and Analysis of the Europe Pharmaceutical Drugs Market:
    Key trends in market are the rising prevalence of chronic and acute diseases, patient expiry of drugs, drug approvals & launch by key players in the market.
  • Increasing incidence and prevalence of chronic and acute wounds in individuals suffering from diseases such as diabetes is a leading factor for growth of the Europe Pharmaceutical Drugs market.
  • The growing healthcare expenditure is also expected to contribute to growth of the Europe Pharmaceutical Drugs market over the forecast period.
  • Global Europe Pharmaceutical Drugs Market, By Product Type:
    Global Europe Pharmaceutical Drugs Market, By Application:

Fusion Pharmaceuticals Appoints James J. O’Leary, M.D. as Chief Medical Officer

Retrieved on: 
Monday, March 23, 2020
Software, Biotechnology, Pharmaceutical, Human resources, Oncology, Health, Professional services, Technology, Life sciences, Articles, Pharmaceutical industry, Natural sciences, Pharmacy, Biotechnology, Biopharmaceutical, Cancer, Oncology, Medication

Fusion Pharmaceuticals Inc. , a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines to treat a broad range of cancers, today announced the appointment of James J. OLeary, M.D., as chief medical officer (CMO).

Key Points: 
  • Fusion Pharmaceuticals Inc. , a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines to treat a broad range of cancers, today announced the appointment of James J. OLeary, M.D., as chief medical officer (CMO).
  • In addition, his background as a medical oncologist provides him with valuable insights and a focus on advancing innovative cancer therapies for patients.
  • Prior to joining the biopharmaceutical industry, Dr. OLeary was a medical reviewer with the U.S. Food and Drug Administration.
  • Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing next-generation radiopharmaceuticals as precision medicines to treat a broad range of cancers.

Emerald Health Pharmaceuticals’ Lead Product Candidate Determined Not to be a Controlled Substance in Canada

Retrieved on: 
Monday, March 23, 2020
Designer drugs, Medication, Cannabinoids, Natural sciences, Health, Chemistry

SAN DIEGO, CA, March 23, 2020 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage company developing medicines based on cannabinoid science, has received the determination from Canadas Controlled Substances Directorate that its lead product candidate, EHP-101, is not a controlled substance under its Controlled Drug and Substance Act (CDSA).

Key Points: 
  • SAN DIEGO, CA, March 23, 2020 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage company developing medicines based on cannabinoid science, has received the determination from Canadas Controlled Substances Directorate that its lead product candidate, EHP-101, is not a controlled substance under its Controlled Drug and Substance Act (CDSA).
  • These determinations by Canada and the US also highlight the important difference between our novel molecules compared to natural cannabinoids.
  • In general, the determination of not being a controlled substance eliminates the costs and complexities otherwise associated with developing controlled substances.
  • About Emerald Health Pharmaceuticals Inc.
    Emerald Health Pharmaceuticals is developing novel product candidates derived from cannabinoids for the treatment of CNS, autoimmune, fibrotic and other diseases.

Physicians Thank Trump, Say More Freedom Needed to Fight COVID-19

Retrieved on: 
Monday, March 23, 2020
Health, Articles, Association of American Physicians and Surgeons, Climate change skepticism and denial, HIV/AIDS denialism, Pharmacy, AAPS, Physician, Medication

But American patients are not receiving the treatments that are being used successfully in France and China .

Key Points: 
  • But American patients are not receiving the treatments that are being used successfully in France and China .
  • In this national crisis, President Trump should invoke his emergency powers to prohibit any interference with physicians who prescribe existing, approved drugs, AAPS states.
  • State regulatory authorities, such as the Texas State Board of Pharmacy, are unjustifiably restricting prescriptions written for these life-saving medications.
  • The Association of American Physicians and Surgeons (AAPS) is a national organization representing physicians in all specialties since 1943.

INTELGENX TO REPORT FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS ON MARCH 26; CONFERENCE CALL TO FOLLOW ON MARCH 27

Retrieved on: 
Monday, March 23, 2020
Health, Articles, Pharmaceuticals policy, Pharmacology, Pharmaceutical industry in China, Pharmacy in China, Science and technology in the People's Republic of China, Pharmaceutical industry, Medication

IntelGenxs superior film technologies, including VersaFilm, VetaFilm and transdermal, allow for next generation pharmaceutical products that address unmet medical needs.

Key Points: 
  • IntelGenxs superior film technologies, including VersaFilm, VetaFilm and transdermal, allow for next generation pharmaceutical products that address unmet medical needs.
  • IntelGenxs innovative product pipeline offer significant benefits to patients and physicians for many therapeutic conditions.
  • IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services.
  • This document may contain forward-looking information about IntelGenx' operating results and business prospects that involve substantial risks and uncertainties.

SOCMA Reinforces Critical Role Specialty Chemical Manufacturers Play in Fighting COVID-19

Retrieved on: 
Friday, March 20, 2020
Natural sciences, Chemistry, Physical sciences, Society of Chemical Manufacturers and Affiliates, Speciality chemicals, Fine chemical, Medication, Chemical industry, United States Department of Homeland Security

ARLINGTON, Va., March 20, 2020 /PRNewswire/ -- The Society of Chemical Manufacturers and Affiliates (SOCMA) today sent a letter to the White House and state governors reinforcing that specialty chemical manufacturers play a critical role in providing essential products to fight the COVID-19 pandemic.

Key Points: 
  • ARLINGTON, Va., March 20, 2020 /PRNewswire/ -- The Society of Chemical Manufacturers and Affiliates (SOCMA) today sent a letter to the White House and state governors reinforcing that specialty chemical manufacturers play a critical role in providing essential products to fight the COVID-19 pandemic.
  • As jurisdictions increasingly consider implementing orders for the closure of nonessential businesses, SOCMA urges all levels of government to designate chemical manufacturing as critical infrastructure and exempt from further operating restrictions."
  • SOCMA welcomes the U.S. Department of Homeland Security's (DHS) classification of chemical manufacturing as a Critical Infrastructure Sector.
  • Our 135 member companies play an indispensable role in the global chemical supply chain, providing specialty chemicals and services to vital markets ranging from aerospace and electronics to pharmaceuticals and agriculture.